Dycine Pharma is proud to announce that it will host the International GMP Compliance Forum 2025, a high-level global gathering focused on best practices, emerging challenges, and the future of Good Manufacturing Practices (GMP) in the pharmaceutical industry. The event will take place on August 12–14, 2025, at the Dycine Innovation Campus in Hyderabad, India.
The forum is expected to bring together regulatory authorities, manufacturing leaders, quality assurance experts, compliance officers, and policy advocates from over 25 countries, including delegates from the US FDA, EMA, CDSCO, WHO, and other leading international health bodies.
“Hosting this forum is both an honor and a responsibility,” said Mr. Sameer Rathi, Head of Compliance at Dycine Pharma. “At a time when global health relies on agile, transparent, and harmonized systems, GMP is the common language that unites us. This forum will be a collaborative space to shape its evolution.”
The 3-day event will feature panel discussions, technical workshops, and live facility walkthroughs showcasing Dycine’s integrated digital compliance systems and AI-enabled quality control protocols. The agenda will also cover key topics such as:
- Harmonizing GMP standards across geographies
- Leveraging data analytics for proactive compliance
- Managing inspections in a post-pandemic world
- Digital batch records and documentation automation
- Sustainability practices in GMP-certified environments
Dycine Pharma, known for its robust manufacturing systems and consistent regulatory track record, was selected to host the forum due to its commitment to setting industry benchmarks in quality, safety, and compliance. The company’s ongoing investment in smart manufacturing infrastructure and its zero-deviation audit history from global agencies make it a model for next-gen compliance excellence.
“This isn’t just about compliance—it’s about trust,” said Dr. Kavita Sharma, Chief Technical Officer at Dycine. “Patients across the world rely on every pill, vial, or tablet we make. This forum reflects our commitment to building that trust through education, collaboration, and innovation.”
Attendees will also receive an exclusive tour of Dycine’s new Quality Intelligence Center, an R&D-driven hub designed to test and validate real-time quality improvements using AI, robotics, and digital twins.
Registrations for the forum will open in early May, with limited seats available for in-person attendees and a virtual participation option for international delegates.
As global regulations evolve and expectations around transparency grow, Dycine Pharma’s initiative to lead such an important conversation demonstrates its proactive role in shaping the industry’s regulatory future.
The International GMP Compliance Forum 2025 isn’t just a conference—it’s a commitment to global pharmaceutical integrity.
